Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks mitochondrial electron transport in the malaria parasite, while proguanil interferes with folate metabolism. Together they produce a synergistic effect that kills the parasite and prevents its replication.

The dosage of Malarone is determined by a qualified prescriber based on the patient’s age, weight, indication (prophylaxis or treatment), and local resistance patterns. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for Malarone in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the medication.

To order Malarone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Malarone offers a convenient once‑daily oral regimen and combines two mechanisms of action, providing high efficacy against chloroquine‑resistant Plasmodium falciparum. Compared with older agents such as chloroquine or mefloquine, it generally has a more favorable side‑effect profile and lower risk of resistance development.

Malarone tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and excessive heat. Keep the product out of reach of children and do not use after the expiry date.

Malarone is taken orally with food or a milky drink to improve absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area and continued for 7 days after leaving. For treatment, it is taken for the prescribed course as directed by the prescriber.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, liver injury, hemolysis in patients with G6PD deficiency, and rare allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they experience rash, jaundice, dark urine, or breathing difficulties.

Malarone should be avoided in individuals with known hypersensitivity to atovaquone, proguanil, or any tablet components, and in patients with severe renal or hepatic impairment unless specifically advised by a physician. Caution is also warranted for pregnant or breastfeeding women and those with G6PD deficiency.